When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option to the need to take tablets ...

GSK said its long-acting injectable HIV drug, Cabenuva, worked better than daily pills for some patients, according to interim results from a late-stage clinical trial. The therapy, developed by ...

The paperwork, sometimes called the patient package insert or medication guide, may have other details about interactions. If you did not get paperwork with Cabenuva, ask your pharmacist to print ...

This was based on a survey filled in alongside one of the trials used for approval, where 532 patients completed a single-item question at Week 48. Results showed 88% preferred Cabenuva compared ...